Note: MEI Pharma's revenues are gauged from an analysis of company filings.
MEI Pharma has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
May 30, 2018
Complete list of funding rounds and total amounts in the Company Report
Trademark applications show the products and services that MEI Pharma is developing and marketing.
MEI Pharma doesn't have any recent trademark applications, indicating MEI Pharma is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
MEI PHARMA Pharmaceuticals for use in the treatment of oncological disorders, neurological disorders, and immune-related disorders
MEI PHARMACEUTICALS Pharmaceuticals for use in the treatment of oncological disorders, neurological disorders, and immune-related disorders
Patent applications show MEI Pharma's intellectual property,
its current capabilities and future direction.
MEI Pharma has applied for 23 patents since 2009.
MEI Pharma's most recent patent was filed in August 2017 for Isoflavonoid Compounds And Methods For The Treatment Of Cancer.Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
Complete list of patent applications
Determine whether MEI Pharma grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof MEI Pharma is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: MEI Pharma vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as MEI Pharma, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to MEI Pharma.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as MEI Pharma and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.